CDTX
Cidara Therapeutics Inc.
$75.47
+$6.76(+9.84%)
63
Overall
--
Value
63
Tech
--
Quality
Market Cap
$1.64B
Volume
741.74K
52W Range
$10.14 - $74.52
Target Price
$74.00
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | -- | -- | -- | -- | -- | -- | $64.4M | $23.3M | $1.3M | ||
| Total Revenue | -- | -- | -- | -- | -- | -- | -- | $64.4M | $23.3M | $1.3M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | -- | -- | -- | -- | -- | -- | $64.4M | $23.3M | $1.3M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-32.3M | $-48.4M | $-55.7M | $-63.3M | $62.6M | $83.9M | $91.8M | $98.0M | $50.3M | $177.4M | ||
| Research & Development | $23.5M | $35.7M | $42.8M | $49.1M | $46.4M | $68.0M | $73.1M | $77.4M | $36.8M | $71.9M | ||
| Research Expense | $23.5M | $35.7M | $42.8M | $49.1M | $46.4M | $68.0M | $73.1M | $77.4M | $36.8M | $71.9M | ||
| Selling, General & Administrative | $8.8M | $12.7M | $12.9M | $14.1M | $16.2M | $15.9M | $18.7M | $20.5M | $13.6M | $20.6M | ||
| General & Administrative Expenses | $8.8M | $12.7M | $12.9M | $14.1M | $16.2M | $15.9M | $18.7M | $20.5M | $13.6M | $20.6M | ||
| Salaries & Wages | $-3.0M | $-4.3M | $-5.7M | $-5.7M | -- | -- | -- | $3.5M | $3.1M | $3.9M | ||
| Depreciation & Amortization | $-461.0K | $-732.0K | $-667.0K | $-523.0K | $300.0K | $300.0K | $200.0K | $143.0K | $100.0K | $200.0K | ||
| Depreciation & Amortization | $-461.0K | $-732.0K | $-667.0K | $-523.0K | $300.0K | $300.0K | $200.0K | $143.0K | $100.0K | $200.0K | ||
| Amortization | $-22.0K | $-5.0K | -- | -- | -- | -- | -- | -- | $77.0K | -- | ||
| Other Operating Expenses | $-32.3M | $-48.4M | $-55.7M | $-63.3M | $-1.1M | $-777.0K | $-655.0K | $-497.0K | $-552.0K | $-1.4M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-32.3M | $-48.4M | $-55.7M | $-63.3M | $-41.7M | $-71.8M | $-42.3M | $-33.5M | $-27.1M | $-176.1M | ||
| EBITDA | $-31.8M | $-47.6M | $-55.1M | $-58.4M | $-40.7M | $-70.8M | $-42.3M | $-33.4M | $-21.7M | $-170.1M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | $21.0K | $12.0K | $2.0K | -- | $100.0K | ||
| Intinc | $120.0K | $271.0K | $-7.0K | $629.0K | $221.0K | $-262.0K | $-212.0K | $191.0K | $2.0M | $5.8M | ||
| Net Non-Operating Interest Income/Expense | $120.0K | $271.0K | $-7.0K | $629.0K | $221.0K | $-262.0K | $-212.0K | $191.0K | $2.0M | $5.8M | ||
| Gain on Sale of Securities | $8.0K | -- | -- | $3.9M | $400.0K | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-8.0K | -- | -- | $-3.7M | $-21.3M | $-12.1M | $-49.6M | $-64.4M | $-23.3M | $-1.3M | ||
| Other Special Charges | -- | -- | -- | $-211.0K | $20.9M | $12.1M | $49.6M | $64.4M | $23.3M | $1.3M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $1.2M | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | $-1.0K | $-5.0K | $-1.2M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-32.2M | $-48.2M | $-55.7M | $-59.0M | $-41.1M | $-71.8M | $-42.3M | $-33.5M | $-22.9M | $-171.5M | ||
| Pre-Tax Income | $-32.2M | $-48.2M | $-55.7M | $-59.0M | $-41.1M | $-72.1M | $-42.5M | $-33.3M | $-25.1M | $-170.3M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-18.0K | $-267.0K | -- | -- | $-1.9M | $-469.0K | $-1.4M | $272.0K | $15.0K | $-1.7M | ||
| NET INCOME | ||||||||||||
| Net Income | $-32.2M | $-48.2M | $-55.7M | $-59.0M | $-41.1M | $-72.1M | $-42.5M | $-33.6M | $-22.9M | $-169.8M | ||
| Net Income (Continuing Operations) | $-32.2M | $-48.2M | $-55.7M | $-59.0M | $-41.1M | $-72.1M | $-42.5M | $-33.6M | $-22.9M | $-170.3M | ||
| Net Income (Discontinued Operations) | $-32.2M | $-48.2M | $-55.7M | $-59.0M | $-41.1M | $-72.1M | $-42.5M | $-33.6M | $-22.9M | $-169.8M | ||
| Net Income (Common Stockholders) | $-32.2M | $-48.2M | $-55.7M | $-69.3M | $-41.1M | $-74.9M | $-42.5M | $-33.6M | $-25.1M | $-169.8M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-43.9M | -- | -- | $-170.8M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-32.3M | $-48.4M | $-55.7M | $-63.3M | $62.6M | $83.9M | $91.8M | $98.0M | $50.3M | $177.4M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $9.9M | $14.5M | $17.5M | $25.1M | $29.1M | $41.6M | $52.5M | $3.5M | $4.4M | $6.3M | ||
| Average Shares Outstanding (Diluted) | $9.9M | $14.5M | $17.5M | $21.4M | $29.1M | $41.6M | $52.5M | $3.5M | $4.4M | $6.3M | ||
| Shares Outstanding | $13.8M | $16.8M | $20.8M | $27.8M | $40.5M | $2.4M | $3.4M | $25.4M | $4.6M | $11.0M | ||
| Basic EPS | -- | -- | -- | -- | $-1.41 | $-1.8 | $-0.81 | $-8.6 | $-5.2 | $-26.75 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-1.41 | $-1.8 | $-0.81 | $-8.6 | $-5.2 | $-26.82 | ||
| Diluted EPS | $-3.25 | $-3.32 | $-3.18 | $-2.76 | $-1.41 | $-1.8 | $-0.81 | $-8.6 | $-5.2 | $-26.75 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-0.81 | $-8.6 | $-5.2 | $-26.82 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | $10.3M | -- | $2.8M | -- | -- | -- | -- | ||
| Basic Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | -- | -- | $0.07 | ||
| Diluted Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | -- | -- | $0.07 | ||
| Interest Expense Operating | -- | -- | -- | -- | -- | -- | -- | $-40.0K | -- | -- | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | -- | $-400.0K | -- | ||
| Other Gand A | $8.8M | $12.7M | $12.9M | $14.1M | $16.2M | $15.9M | $18.7M | $20.5M | $13.6M | $20.6M | ||
| Otherunder Preferred Stock Dividend | -- | -- | -- | $10.3M | -- | $2.8M | -- | -- | -- | -- | ||
| Preferred Stock Dividends | -- | -- | -- | $10.3M | -- | $2.8M | -- | -- | -- | -- | ||
| Rent And Landing Fees | $8.8M | $12.7M | $12.9M | $14.1M | -- | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | -- | -- | -- | -- | -- | -- | $1.0K | $5.0K | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | -- | -- | $1.2M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CDTX | $75.47 | +9.8% | 741.74K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cidara Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW